SG10201911225WA - Methods of treating neurodegenerative diseases - Google Patents
Methods of treating neurodegenerative diseasesInfo
- Publication number
- SG10201911225WA SG10201911225WA SG10201911225WA SG10201911225WA SG10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- neurodegenerative diseases
- treating neurodegenerative
- treating
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477535P | 2017-03-28 | 2017-03-28 | |
| US201762532696P | 2017-07-14 | 2017-07-14 | |
| US201762577559P | 2017-10-26 | 2017-10-26 | |
| US201762580359P | 2017-11-01 | 2017-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911225WA true SG10201911225WA (en) | 2020-01-30 |
Family
ID=62063590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911225WA SG10201911225WA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
| SG11201908326Y SG11201908326YA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908326Y SG11201908326YA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200131255A1 (en) |
| EP (1) | EP3601337A1 (en) |
| JP (2) | JP2020515543A (en) |
| KR (1) | KR20190133162A (en) |
| CN (2) | CN117205311A (en) |
| AU (1) | AU2018244224A1 (en) |
| CA (1) | CA3055758A1 (en) |
| IL (1) | IL269106A (en) |
| MA (1) | MA48996A (en) |
| MX (1) | MX2019011423A (en) |
| SG (2) | SG10201911225WA (en) |
| TW (2) | TW202400231A (en) |
| WO (1) | WO2018183175A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3303386A1 (en) | 2015-06-05 | 2018-04-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190261A1 (en) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
| EP3551220A1 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| MX2019006330A (en) | 2016-12-07 | 2019-09-26 | Genentech Inc | Anti-tau antibodies and methods of their use. |
| MA47499A (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | ANTI-TAU BODIES AND THEIR METHODS OF USE |
| PE20212324A1 (en) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| IL310382A (en) * | 2021-08-27 | 2024-03-01 | Genentech Inc | Methods of treating tau pathologies |
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
| JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ES2375931T3 (en) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | HUMANIZATION OF ANTIBODY MURINO. |
| JP2002510481A (en) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| JP2003512019A (en) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | Polypeptide variants with altered effector functions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| MXPA02003456A (en) | 1999-10-04 | 2002-10-23 | Medicago Inc | Method for regulating transcription of foreign genes in the presence of nitrogen. |
| JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
| JP2003531588A (en) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | Multivalent antibodies and their uses |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| BR0309145A (en) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Cells from which the genome is modified |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| ATE503829T1 (en) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PL212899B1 (en) | 2002-12-16 | 2012-12-31 | Genentech Inc | Immunoglobulin variants and uses thereof |
| NZ541282A (en) | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| JPWO2005053742A1 (en) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | Medicament containing antibody composition |
| JP5128935B2 (en) | 2004-03-31 | 2013-01-23 | ジェネンテック， インコーポレイテッド | Humanized anti-TGF-β antibody |
| EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| PL2059533T3 (en) | 2006-08-30 | 2013-04-30 | Genentech Inc | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2012049570A1 (en) | 2010-10-11 | 2012-04-19 | Panima Pharmaceuticals Ag | Human anti-tau antibodies |
| BR112015003326A2 (en) | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
| CN111205368B (en) | 2012-12-21 | 2023-05-09 | 比奥根Ma公司 | Human anti-TAU antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| TWI734975B (en) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| EP3303386A1 (en) * | 2015-06-05 | 2018-04-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
-
2018
- 2018-03-26 SG SG10201911225WA patent/SG10201911225WA/en unknown
- 2018-03-26 CN CN202311141590.5A patent/CN117205311A/en active Pending
- 2018-03-26 TW TW112109248A patent/TW202400231A/en unknown
- 2018-03-26 MA MA048996A patent/MA48996A/en unknown
- 2018-03-26 WO PCT/US2018/024300 patent/WO2018183175A1/en unknown
- 2018-03-26 EP EP18720677.6A patent/EP3601337A1/en active Pending
- 2018-03-26 CN CN201880021209.2A patent/CN110494446A/en active Pending
- 2018-03-26 SG SG11201908326Y patent/SG11201908326YA/en unknown
- 2018-03-26 AU AU2018244224A patent/AU2018244224A1/en active Pending
- 2018-03-26 CA CA3055758A patent/CA3055758A1/en active Pending
- 2018-03-26 JP JP2019552543A patent/JP2020515543A/en active Pending
- 2018-03-26 KR KR1020197026447A patent/KR20190133162A/en not_active Application Discontinuation
- 2018-03-26 MX MX2019011423A patent/MX2019011423A/en unknown
- 2018-03-26 TW TW107110248A patent/TW201836640A/en unknown
-
2019
- 2019-09-03 IL IL26910619A patent/IL269106A/en unknown
- 2019-09-19 US US16/576,249 patent/US20200131255A1/en not_active Abandoned
-
2021
- 2021-01-15 US US17/150,201 patent/US20210284720A1/en active Pending
-
2023
- 2023-01-12 JP JP2023002900A patent/JP2023055720A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201908326YA (en) | 2019-10-30 |
| TW201836640A (en) | 2018-10-16 |
| CN110494446A (en) | 2019-11-22 |
| TW202400231A (en) | 2024-01-01 |
| KR20190133162A (en) | 2019-12-02 |
| IL269106A (en) | 2019-11-28 |
| US20210284720A1 (en) | 2021-09-16 |
| RU2019130976A (en) | 2021-04-28 |
| EP3601337A1 (en) | 2020-02-05 |
| MA48996A (en) | 2020-02-05 |
| WO2018183175A1 (en) | 2018-10-04 |
| CN117205311A (en) | 2023-12-12 |
| MX2019011423A (en) | 2019-11-01 |
| JP2020515543A (en) | 2020-05-28 |
| US20200131255A1 (en) | 2020-04-30 |
| AU2018244224A1 (en) | 2019-09-19 |
| CA3055758A1 (en) | 2018-10-04 |
| JP2023055720A (en) | 2023-04-18 |
| RU2019130976A3 (en) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| IL269106A (en) | Methods of treating neurodegenerative diseases | |
| HK1245078A1 (en) | Methods of treating a neurodegenerative disease | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| IL253118A0 (en) | Methods of treating inflammatory diseases | |
| HK1252037A1 (en) | Methods of treating inflammatory diseases | |
| ZA201903873B (en) | Methods of treating cochlear synaptopathy | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| HK1247818A1 (en) | Method of treating diseases | |
| GB201706406D0 (en) | Method of treatment | |
| GB201815588D0 (en) | Method of treatment | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
| GB201602802D0 (en) | Method of treatment | |
| HK1243937A1 (en) | Methods of treating diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| EP3426280A4 (en) | Methods of treating neurodegenerative diseases | |
| GB201714316D0 (en) | Treatement of neurodegenerative diseases | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201720439D0 (en) | Method of treatment |